Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Healthtrust
Harvard Business School
Novartis
Baxter
Daiichi Sankyo
Teva
Federal Trade Commission
Mallinckrodt
AstraZeneca

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,790,458

« Back to Dashboard

Which drugs does patent 6,790,458 protect, and when does it expire?

Patent 6,790,458 protects SUSTOL and is included in one NDA.

This patent has sixteen patent family members in ten countries.
Summary for Patent: 6,790,458
Title: Pharmaceutical compositions using semi-solid delivery vehicle
Abstract:A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
Inventor(s): Ng; Steven Y. (San Francisco, CA), Shen; Hui-Rong (Fremont, CA), Heller; Jorge (Woodside, CA)
Assignee: AP Pharma Inc. (Redwood City, CA)
Application Number:10/409,408
Patent Claim Types:
see list of patent claims
Composition; Compound; Delivery; Use; Process;

Drugs Protected by US Patent 6,790,458

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Heron Theraps Inc SUSTOL granisetron INJECTION, EXTENDED RELEASE;SUBCUTANEOUS 022445-001 Aug 9, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,790,458

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,613,355 Semi-solid delivery vehicle and pharmaceutical compositions ➤ Sign Up
8,252,305 Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron ➤ Sign Up
8,252,306 Process for preparing a semi-solid delivery vehicle comprising granisetron ➤ Sign Up
8,715,710 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron ➤ Sign Up
6,861,068 Pharmaceutical compositions using semi-solid delivery vehicle ➤ Sign Up
8,252,304 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,790,458

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I407966 ➤ Sign Up
Taiwan 200616650 ➤ Sign Up
South Korea 20070083851 ➤ Sign Up
Japan 2017008113 ➤ Sign Up
Japan 2012107064 ➤ Sign Up
Japan 2008514646 ➤ Sign Up
Japan 6057972 ➤ Sign Up
Japan 2015034182 ➤ Sign Up
Hong Kong 1213477 ➤ Sign Up
Spain 2529574 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Dow
Farmers Insurance
Accenture
Cerilliant
QuintilesIMS
Cantor Fitzgerald
Boehringer Ingelheim
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot